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1. BACKGROUND {#mgg31256-sec-0005}
=============

Down syndrome (trisomy 21; T21) imposes a great burden to the society. The prevalence of T21 in Thailand is 1.2 per 1,000 live births (Jaruratanasirikul et al., [2017](#mgg31256-bib-0019){ref-type="ref"}). High‐throughput DNA‐based noninvasive prenatal screening (NIPS) has been rapidly adopted in clinical cares since it became commercially available in late 2011. Recent large‐scale studies have consistently reported excellent performance of NIPS to detect fetal T21, trisomy 18 (T18), trisomy 13 (T13), and sex chromosome aneuploidies (SCA) in the first and second trimester of pregnancy (Bianchi et al., [2014](#mgg31256-bib-0004){ref-type="ref"}; Cuckle, Benn, & Pergament, [2015](#mgg31256-bib-0008){ref-type="ref"}; Gil et al., [2017](#mgg31256-bib-0014){ref-type="ref"}; Hui et al., [2015](#mgg31256-bib-0018){ref-type="ref"}; McCullough et al., [2014](#mgg31256-bib-0025){ref-type="ref"}; Nicolaides, Syngelaki, Ashoor, Birdir, & Touzet, [2012](#mgg31256-bib-0027){ref-type="ref"}; Sago, Sekizawa, & Japan, [2015](#mgg31256-bib-0033){ref-type="ref"}; Samura et al., [2017](#mgg31256-bib-0036){ref-type="ref"}; Shaw, Chen, & Cheng, [2013](#mgg31256-bib-0038){ref-type="ref"}; Willems et al., [2014](#mgg31256-bib-0046){ref-type="ref"}; Zhang et al., [2015](#mgg31256-bib-0048){ref-type="ref"}). Most NIPS platforms utilize quantitative "counting" methods (whole‐genome sequencing; WGS) where fetal chromosome copy number is determined by comparing the absolute number of sequence reads from the chromosome(s) of interest (ie chromosome 21) to reference chromosome(s). Fetal trisomy is inferred when this ratio is above a predetermined threshold (Futch et al., [2013](#mgg31256-bib-0013){ref-type="ref"}). Fetal fraction (FF), the amount of the cell‐free DNA in the maternal blood that is of fetal origin, is essential for accurate test results (Wataganara, Bui, Choy, & Leung, [2016](#mgg31256-bib-0042){ref-type="ref"}). Placental production (apoptosis) and renal excretion of cell‐free DNA may be varied in different racial origins (DiNonno et al., [2019](#mgg31256-bib-0011){ref-type="ref"}; Heazell, Whitworth, Duley, & Thornton, [2015](#mgg31256-bib-0017){ref-type="ref"}; Ryan et al., [2016](#mgg31256-bib-0032){ref-type="ref"}; Wataganara, Chen, et al., [2005](#mgg31256-bib-0043){ref-type="ref"}; Wataganara, Metzenbauer, Peter, Johnson, & Bianchi, [2005b](#mgg31256-bib-0044){ref-type="ref"}). However, previous publications suggested that performance of WGS‐based NIPS is not affected by ethnic backgrounds (Bianchi et al., [2012](#mgg31256-bib-0005){ref-type="ref"}; Manotaya et al., [2016](#mgg31256-bib-0024){ref-type="ref"}).

The NIPS using WGS and single‐nucleotide polymorphism (SNP) approaches may perform differently (Cuckle, [2017](#mgg31256-bib-0007){ref-type="ref"}; Salomon et al., [2017](#mgg31256-bib-0034){ref-type="ref"}). Unique advantages of SNP‐based NIPS are (a) differentiation between maternal and fetal contributions of the sequence reads, thus help flagging the samples with maternal mosaicism which may cause false positive (FP) results, and (b) detection of additional haplotypes, thus help identifying triploidy, uniparental disomy (molar pregnancy), and vanishing twin (VT) which may escape WGS methods (Levy & Norwitz, [2013](#mgg31256-bib-0023){ref-type="ref"}). If needed, additional sets of SNPs are targeted for identification of microdeletions (Gross et al., [2016](#mgg31256-bib-0015){ref-type="ref"}). However, SNPs approach may have a higher no‐call rate than WGS methods, especially in women with consanguinity, surrogacy, and transplantation of solid organ or bone marrow (Zimmermann et al., [2012](#mgg31256-bib-0050){ref-type="ref"}). A clinical performance study of SNP‐based NIPS performed in USA reported approximately 80% positive predictive value (PPV) with very low negative predictive value (NPV) (Dar et al., [2014](#mgg31256-bib-0010){ref-type="ref"}). Published data from SNP‐based NIPS are more limited than those of WGS approach (Badeau et al., [2017](#mgg31256-bib-0002){ref-type="ref"}). The proprietary library, which is not population‐specific, contained 11,000 to 19,488 SNPs covering chromosomes 21, 18, 13, X, and Y to determine allele identity (Zimmermann et al., [2012](#mgg31256-bib-0050){ref-type="ref"}). The library has recently been truncated to 13,392 SNPs (Ryan et al., [2016](#mgg31256-bib-0032){ref-type="ref"}). We aimed to assess our population‐specific performance of SNPs‐based NIPS due to the concerns of possible differences of SNP allele frequency and FF in Thai women.

2. METHODS {#mgg31256-sec-0006}
==========

2.1. Ethical compliance {#mgg31256-sec-0007}
-----------------------

This study was approved by the Siriraj Institutional Review Board (COA Si 742/2017) as parts of an assessment prior to technology transfer with our academic laboratory (Department of Clinical Pathology, Faculty of Medicine Siriraj Hospital).

This is a retrospective analysis of collected data from SNP‐based NIPS (Panorama^TM^, Natera Inc.) in Thailand from October 1, 2013 until May 31, 2018. At the time of data collection, the test was exclusively self‐paid. Only samples from pregnant women with singleton pregnancy were included. Samples were excluded in cases of gestational age \<9 weeks, multiple gestation, donor egg pregnancy, surrogate carrier, missing patient information or incomplete consent documents, sample received \>6 days after collection, insufficient blood volume (\<13 ml), wrong collection tube used, or if the sample was apparently damaged. This study was conducted prior to the twins panel of this test has become available (Norwitz et al., [2019](#mgg31256-bib-0030){ref-type="ref"}).

Written informed consent was obtained from all women opted for SNP‐based NIPS. Maternal age (calculated from date of birth), weight, and gestational age were routinely requested for each sample. Samples that passed quality‐control metrics were processed at a single commercial laboratory (Natera Inc.). Validated methodologies were used for isolation of cell‐free DNA, polymerase chain reaction amplification of targeting SNPs on chromosomes 21, 18, 13, X, and Y, high‐throughput sequencing, and risk scoring with a proprietary algorithm (Nicolaides, Syngelaki, Gil, Atanasova, & Markova, [2013](#mgg31256-bib-0029){ref-type="ref"}; Pergament et al., [2014](#mgg31256-bib-0031){ref-type="ref"}). The FF was estimated from allelic ratios of SNPs on chromosomes that are never trisomic or monosomic in a viable pregnancy, and was embedded in the SNP sequencing process (Wataganara et al., [2016](#mgg31256-bib-0042){ref-type="ref"}). All samples with a risk score ≥99/100 and \<1/10,000 were reported as high‐ and low‐risk for aneuploidies, respectively. Additional haplotypes detected on SNPs sequencing heightened the risks of triploidy/VT. A second blood draw (redraw) was requested if total cell‐free DNA, FF, or signal‐to‐noise ratio failed quality‐control metrics. This could be due to sample impurity, insufficient yield of DNA after extraction, or failure of DNA sequencing. Redraw was not offered in cases of uninformative SNPs pattern including; large regions (\>25%) loss of heterozygosity, poor fit of the data to the model, or suspected maternal or fetal mosaicism (Dar et al., [2014](#mgg31256-bib-0010){ref-type="ref"}). Genetic amniocentesis was offered to those with high‐risk calls or repeated inconclusive results (no‐calls).

Follow‐up information on high‐risk results was obtained by a single partner laboratory. (Bangkok Cytogenetics Center Co. Ltd.) Clinical follow‐up was completed in December 2018. Results were categorized as follows: (a) true positive (TP: high‐risk samples that were confirmed by prenatal or postnatal diagnostic testing, or based on clinical evaluation at birth), (b) false positive (FP: high‐risk samples that were shown to be euploid by follow‐up testing or based on clinical evaluation at birth, (c) false negative (FN: low‐risk samples that were reported as aneuploid by the providers). To encourage more validated positive cases and to find FPs, an insurance policy was provided by the partner laboratory from May 2017 to reimburse the cost of invasive diagnostic tests for women with high‐risk call. This insurance policy could also minimize unreported FNs because providers were motivated to report of missed calls forT21, T18, and T13, whereby the woman would be reimbursed for 100,000 Thai Bahts (approximately 3,000 US Dollars).

2.2. Statistical analysis {#mgg31256-sec-0008}
-------------------------

Categorical variables were expressed as number and percentage. Continuous variables were expressed as percentage, means, standard deviation (*SD*), median and ranges (minimum‐maximum). Samples with conclusive and repeated inconclusive results (no‐calls) were compared for maternal age, weight, gestational age at first draw, and FF, using independent *t* test or Mann--Whitney *U* test. Due to wide distribution of FF and relatively small sample size, FFs were not expressed as gestational week‐specific multiples of the median, and linear regression analysis between FF and other demographic variables were not performed (Ashoor, Syngelaki, Poon, Rezende, & Nicolaides, [2013](#mgg31256-bib-0001){ref-type="ref"}). The performance was defined by aneuploidy‐specific PPV (TP/(TP + FP)).

Because most of the low‐risk samples were not confirmed by genetic test at the time of birth, true negative (TN) could not be accurate. We therefore chose not to calculate NPV (TN/(TN + FN)). Sensitivity and specificity were not reported because our screened population was biased (not every Thai women received SNP‐based NIPS).

SPSS version 18 (SPSS Inc.) was used for analyzing data. P value less than 0.05 was considered significant.

3. RESULTS {#mgg31256-sec-0009}
==========

The study enrollment (*n* = 8,659) is summarized in Figure [1](#mgg31256-fig-0001){ref-type="fig"}. The majority of the samples were from private medical providers. (Bangkok Cytogenetics Center Co. Ltd., personal communication) After exclusion of 87 samples from non‐Thai women and twins, 8,572 samples were analyzed. Indications for NIPS are as follows; maternal age ≥35 years (*n* = 3,874; 45.2%), parental anxiety (physician discretion) (*n* = 2,897:33.8%), positive first trimester combined test (\>1:250) (*n* = 1,569:18.3%), abnormal ultrasound examination (*n* = 189:2.2%), and undefined (*n* = 43:0.5%). Comparative analysis of the test performance in each category was not performed due to inadequacy of power. After the first draw, the tests were unreportable in 462 women (5.4%), of which 1 (0.2%) was due to uninformative SNP pattern. One woman opted for genetic amniocentesis at this point. For 460 women with low FF, a second blood draw could settle 323 (70%) cases. At the end, the tests were conclusive in 8,434 samples (98.4%); with 131 high‐risk calls (1.6%). After exclusion of 1 woman who immediately opted for genetic amniocentesis, and inclusion of 1 uninformative SNPs pattern, there were138 women (1.6%) with repeated inconclusive results.

![Flow chart for results of the study. NIPS, noninvasive prenatal screening; SCA, sex chromosome aneuploidies; SNP, single nucleotide polymorphism; T13, trisomy 13; T18, trisomy 18; T21, trisomy 21; VT, vanishing twin; XO, monosomy X](MGG3-8-e1256-g001){#mgg31256-fig-0001}

Baseline characteristics are summarized in Table [1](#mgg31256-tbl-0001){ref-type="table"}. Maternal age and gestational age of samples with conclusive and repeated inconclusive results were not significantly different (*p* \> .05). Women with reportable results had significantly lower weight and higher FF than those with repeated inconclusive results (*n* = 136; after exclusion of 2 subjects; 1 who chose genetic amniocentesis after low FF from the first draw and 1 with uninformative SNPs pattern) (*p* \< .01).

###### 

Characteristics of samples with conclusive and repeated inconclusive results

+-------------------------------+--------------------------------------------------------------+----------------------------------+---------------------------------------------------------+------------+
|                               | Total (*n* = 8,571[^a^](#mgg31256-note-0003){ref-type="fn"}) | Conclusive results (*n* = 8,434) | Repeated inconclusive results (*n* = 137)               | *p* value  |
+===============================+==============================================================+==================================+=========================================================+============+
| MA (years) (mean ± *SD*)      | 35.0 ± 3.5                                                   | 35 ± 3.5                         | 35.1 ± 4.4                                              | .6         |
+-------------------------------+--------------------------------------------------------------+----------------------------------+---------------------------------------------------------+------------+
| MW (lbs.) (mean ± *SD*)       | 125.7 ± 22.4                                                 | 125.2 ± 22.0                     | 134.7 ± 26.7                                            | **\<.001** |
+-------------------------------+--------------------------------------------------------------+----------------------------------+---------------------------------------------------------+------------+
| GA at first draw; mean ± *SD* | 13.2 ± 2.1                                                   | 13.2 ± 2.1                       | 13.3 ± 2.1                                              | .3         |
+-------------------------------+--------------------------------------------------------------+----------------------------------+---------------------------------------------------------+------------+
| FF; median (%) (min‐max)      | N/A[^b^](#mgg31256-note-0004){ref-type="fn"}                 | 10.5% (2.6--37.9)                | 3.8% (1--14.1)[^c^](#mgg31256-note-0005){ref-type="fn"} | **\<.001** |
|                               |                                                              |                                  |                                                         |            |
|                               |                                                              |                                  | (*n* = 80)                                              |            |
+-------------------------------+--------------------------------------------------------------+----------------------------------+---------------------------------------------------------+------------+

Abbreviations: FF, fetal fraction; GA, gestational age; lbs, pounds; MA, maternal age; MW, maternal weight; *SD*, standard deviation; SNP, single‐nucleotide polymorphism.

After exclusion of one woman who opted for genetic amniocentesis after FF in the first draw was too low. One uninformative SNP pattern was included in repeated inconclusive result.

Median FF could not be calculated because 57/137 (42%) of repeated inconclusive results had unmeasurable FF.

Median (min‐max) was calculated from those with measurable FF (80/137), yet unreportable result.

John Wiley & Sons, Ltd

Table [2](#mgg31256-tbl-0002){ref-type="table"} demonstrates the clinical performance of SNP‐based NIPS. Results of confirmatory genetic test were available in of 106/131 (80.9%) of those with high‐risk calls. The PPVs for T21, T18, and T13 were 94%, 100%, and 58.3%, respectively, with an average PPV for detection of these 3 common autosomal trisomies of 89.6%. The PPVs for monosomy X (XO), SCA other than XO, and triploidy/VT were 66.7%, 70%, and 57.1%, respectively. Fetal karyotypes were available in 52/138 women with repeated unreportable results (1 uninformative SNP included), none of which had aneuploidies. We did not have molar pregnancy reported in this cohort.

###### 

Clinical performance of single‐nucleotide polymorphism‐based noninvasive prenatal screening in Thai women with conclusive results (*n* = 8,434)

  Types of Aneuploidy       High‐risk calls   Confirmatory testing (%)   TP   FP   PPV (%) (95% CI)    FN
  ------------------------- ----------------- -------------------------- ---- ---- ------------------- ----
  T21                       63                50 (79.4)                  47   3    94 (83.5--98.0)     1
  T18                       20                15 (75)                    15   0    100.0               0
  T13                       13                12 (92.3)                  7    5    58.3 (36.8--77.1)   0
  Overall (T21 + T18+T13)   96                77 (80.2)                  69   8    89.6 (81.2--94.5)   0
  XO                        18                12 (66.7)                  8    4    66.7 (42.9--84.2)   0
  SCA other than XO         10                10 (100)                   7    3    70 (50.5--81.8)     0
  Triploidy/VT              7                 7 (100)                    4    3    57.1 (44.9--87.9)   0
  Total                     131               106 (80.9)                 84   15   84.9 (77.2--90.3)   0

Abbreviations: CI, confidence interval; FP, false positive; PPV, positive predictive value; SCA, sex chromosome aneuploidies; T13, trisomy 13; T18, trisomy 18; T21, trisomy 21; TP, true positive; VT, vanishing twin; XO, monosomy X.

John Wiley & Sons, Ltd

Table [3](#mgg31256-tbl-0003){ref-type="table"} compares the performance of SNP‐based NIPS from previous publications searchable in Pubmed. Searching terms were single nucleotide polymorphism, NIPS, noninvasive prenatal testing, Panorama. Systematic reviews were excluded. The PPVs for detection of T21 and T18 in Thai women were high, and comparable with other previous publications.

###### 

Summary of performance of single nucleotide‐based noninvasive prenatal screening for detection of trisomy 21 (T21), trisomy 18 (T18), trisomy 13 (T13), monosomy X (XO), sex chromosome aneuploidies (SCA) other than XO, and triploidy

  Publication                                                                         Sample size   Ethnicity                                                                 Study design[^a^](#mgg31256-note-0009){ref-type="fn"}   Priori risk                                   GA (weeks)                                                                       FF (%)                                                                                                                            No call (%)                                               T21 PPV (%)                                                      T18 PPV (%)                                                  T13 PPV (%)                                                  XO PPV (%)                                                SCA PPV (%)   Triploidy PPV (%)                                                                                                 Remarks
  ----------------------------------------------------------------------------------- ------------- ------------------------------------------------------------------------- ------------------------------------------------------- --------------------------------------------- -------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------ --------------------------------------------------------- ------------- ----------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------
  Zimmermann B, et al. Prenat Diagn [2012](#mgg31256-bib-0050){ref-type="ref"}        166           N/A                                                                       Prospective                                             Women with known fetal karyotypes             Median: 17 (euploid samples) and 17.5 (aneuploidies samples)                     Mean 12 (2.0--30.8)                                                                                                               0                                                         100 (11/11)                                                      100% (3/3)                                                   100 (2/2)                                                    100 (1/1)                                                 66.7 (2/3)    N/A                                                                                                               Development study
  Nicolaides KH, et al. Prenat Diagn [2013](#mgg31256-bib-0029){ref-type="ref"}       242           N/A                                                                       External validation                                     Women underwent CVS for fetal karyotyping     Median 13.1 (11.3--13.9)                                                         N/A                                                                                                                               5.4 (13/242)                                              100 (25/25)                                                      100 (3/3)                                                    100 (1/1)                                                    100 (2/2)                                                 100 (1/1)     100 (1/1)                                                                                                         External validation study
  Samango‐Sprouse C, et al. Prenat Diagn [2013](#mgg31256-bib-0035){ref-type="ref"}   201           N/A                                                                       Cross‐sectional                                         Archived samples with known fetal karyotype   Mean 13.2 (euploid samples) and 15.3 (aneuploid samples)                         Mean 10.9 (euploid samples) and 12.1 (aneuploid samples)                                                                          6 (12/201)                                                N/A                                                              N/A                                                          N/A                                                          N/A (sensitivity 91.7% (CI: 61.5--99.8)                   100 (3/3)     N/A                                                                                                               Development study for SCA
  Pergament E, et al. Obstet Gynecol [2014](#mgg31256-bib-0031){ref-type="ref"}       1,064         N/A                                                                       Prospective                                             Mixed risk                                    Median 14.1 (7.6--40.6: euploid samples) and 14.6 (8--38.9; aneuploid samples)                                                                                                                                     8.1 (85/1,064)                                            98.1 (103/105)                                                   100 (58/58)                                                  12/12 (100)                                                  90 (9/10)                                                 N/A           N/A                                                                                                               Clinical experience study
  Dar P, et al. AJOG [2014](#mgg31256-bib-0010){ref-type="ref"}                       30,705        N/A                                                                       Retrospective                                           Mixed‐risk                                    Median 12.6 (3.1--40.9)                                                          Mean 10.2 (GA‐specific *SD* available in the paper)                                                                               1 (317/30,705)                                            90.9 (140/154)                                                   93.1 (27/29)                                                 38.1 (8/21)                                                  50 (9/18)                                                 N/A           N/A                                                                                                               Large‐scale clinical experience study
  Hall MP, et al. PLoS One [2014](#mgg31256-bib-0016){ref-type="ref"}                 64            N/A                                                                       Case‐control                                            Archived samples with known fetal karyotype   Median 16 (12.1--22.7)                                                           Median 11.1 (2.2--30.4)                                                                                                           *N*/A                                                     *N*/A                                                            *N*/A                                                        100 (15/15)                                                  *N*/A                                                     *N*/A         *N*/A                                                                                                             Development study for T13
  Nicolaides KH, et al. Fetal Diagn Ther [2014](#mgg31256-bib-0028){ref-type="ref"}   56            Caucasian 82.1% (46/56), Afro‐Caribbean 10.7% (6/56), Asian 7.2% (4/56)   Case‐control                                            Archived samples with known fetal karyotype   11--13                                                                           Median 10.1 (3.5--18.1: euploid samples) 23.4 (14.3--40.8: diandric triploid samples), 2.8 (1.4--3.5: digynic triploid samples)   8.3 (4/48 of euploid samples)                             N/A                                                              N/A                                                          N/A                                                          N/A                                                       N/A           100 (?)(4/4 detection of multiple paternal haplotypes, suggesting either diandric triploidy or dizygotic twins)   Study for triploidy
  Curnow KJ, et al. AJOG [2015](#mgg31256-bib-0009){ref-type="ref"}                   30,795        N/A                                                                       Retrospective                                           Mixed                                         Median 12.6 (3.1--40.9)                                                          Mean 10.2 (GA‐specific *SD* available in the paper)                                                                               1 (317/30,705)                                            N/A                                                              N/A                                                          N/A                                                          N/A                                                       N/A           96.1 (?) (73/76 confirmed diandric triploidy and twins)                                                           Large‐scale clinical experience study for triploidy, molar, and vanishing twins from detection of additional fetal haplotypes
  Eiben B, et al. Ultrasound Int Open [2015](#mgg31256-bib-0012){ref-type="ref"}      2,942         N/A                                                                       Retrospective                                           Mixed                                         \>9                                                                              Mean 10.2 (GA‐specific *SD* available in the paper)                                                                               2.2 (66/2,942)                                            97.4 (38/39)                                                     88.9 (8)                                                     62.5 (5/8)                                                   80 (4/5)                                                  N/A           100 (4/4)                                                                                                         Clinical experience in Germany and Austria
  Ryan A, et al. FDT [2016](#mgg31256-bib-0032){ref-type="ref"}                       587           N/A                                                                       Case‐control                                            Archived samples with known fetal karyotype   Median 13 (9.0--36.7; euploid samples) and 14.6 (9.0--36.0: aneuploid samples)   Median 10 (2.0--46.6 euploid samples) and 11.6 (1.4--50.0 aneuploid samples)                                                      2.3                                                       N/A (sensitivity 99.4% (166/167)), specificity 100% (373/373))   N/A (sensitivity 100% (28/28), specificity 100% (512/512))   N/A (sensitivity 100% (14/14), specificity 100% (526/526))   N/A (sensitivity 100% (7/7), specificity 100% (533/533)   N/A           N/A (sensitivity 100% (4/4), specificity 100% (540/540)                                                           Validation of enhanced test version
  DiNonno W, et al. J Clin Med [2019](#mgg31256-bib-0011){ref-type="ref"}             1,035,844     N/A                                                                       Retrospective                                           Mixed                                         N/A                                                                              N/A                                                                                                                               N/A                                                       95.7 (1,036/1,083)                                               93.9 (447/476)                                               79.6 (148/186)                                               91.0 (272/299)                                            N/A           N/A                                                                                                               Only for available follow‐up information for pregnancies in women with high‐risk SNP‐based NIPS results from 2014--2017
  Panchalee T, et al.                                                                 8,572         Thai 100% (8,572/8,572)                                                   Retrospective                                           Mixed                                         Median 10.5 (2.6--37.9)                                                          Mean 13.2 ± 2.1                                                                                                                   1.6% (138/8,571) (1 uninformative SNP pattern included)   94 (47/50)                                                       100 (15/15)                                                  58.3 (7/12)                                                  66.7 (8/12)                                               70 (7/10)     57.1 (4/7)                                                                                                        Clinical experience in Thailand

Abbreviations: CVS, chorionic villous sampling; FF, fetal fraction; GA, gestational age; N, No; N/A, not available; NIPS, noninvasive prenatal screening; PPV, positive predictive value; SCA, sex chromosome aneuploidies other than XO; *SD*, standard deviation; SNP, single‐nucleotide polymorphism; Y, Yes.

Prospective = samples drawn prior to invasive prenatal diagnosis, archived samples = drawn as part of existing screening program with known outcomes, mixed = mixed of both study design.

John Wiley & Sons, Ltd

4. DISCUSSION {#mgg31256-sec-0010}
=============

High PPVs for detection of T21 and T18 in Thai women of mixed baseline risks with SNP‐based NIPS are consistent with studies conducted elsewhere (Table [3](#mgg31256-tbl-0003){ref-type="table"}). The PPVs are prevalence‐dependent, and can be used for counseling in specific population. Our redraw rate of 5.4% was similar to a previous study (redraw 5.4% at ≥10 weeks' gestation) (Dar et al., [2014](#mgg31256-bib-0010){ref-type="ref"}). Repeated inconclusive results (no calls) in Thai population are relatively low (1.6%); and persistently low FF remains an important cause. Although the SNPs library of the test was not developed from the population intended to screen, uninformative SNPs pattern is not a common reason for no‐calls. Our sample size was too small for calculation of PPVs fortriploidy and VT.

Approximately 79% of women in our cohort chose to have SNP‐based NIPS as a first‐tier test due to advanced age and maternal anxiety (physician discretion). Public health care system in Thailand does not subsidize first trimester screening for T21, and combined first trimester screening or NIPS are self‐paid. Thai women need to choose between combined tests and NIPS; considering the advantages and limitations of different technologies, specific gestational situations, psychological status, and financial constraints. Prenatal diagnosis of common aneuploidies in Thailand is often made by genetic amniocentesis in the second trimester. This makes the landscape of prenatal screening and diagnosis in Thailand quite different from developed countries whose data dominate the publication domain.

Although most of human genomes are identical, a relatively small number of SNP, whichis an individual variation at a single position in DNA sequence that occurs in about every 300nucleotides,are varied in different ancestral descents (Yang, Wang, Lin, Chen, & Chen, [2012](#mgg31256-bib-0047){ref-type="ref"}; Zhou & Wang, [2007](#mgg31256-bib-0049){ref-type="ref"}). Instrumental SNP markers for a genealogic study are chosen according to their ethnic‐specific distribution (Tocharoentanaphol et al., [2008](#mgg31256-bib-0040){ref-type="ref"}). The selection of \<20,000 SNPs on chromosome of interest from 10 million SNPs in human genome to create the proprietary genomiclibrary was confidential (Wataganara et al., [2016](#mgg31256-bib-0042){ref-type="ref"}). Algorithm of SNP‐based NIPS is morecomplex than those of WGS approaches, as it tends to a very shallow depth of sequencing at any given polymorphic locus. Measurement of FF with SNPs approach is equally accurate across populations because the quantitation assays are unbiased, uniformly covering chromosome 1 to 12, and maximizing the number of informative loci by targeting SNPs with high minor‐allele frequencies in the HapMap dataset ([ftp://ftp.ncbi.nlm.nih.gov/hapmap/](http://ftp://ftp.ncbi.nlm.nih.gov/hapmap/)) (Juneau et al., [2014](#mgg31256-bib-0020){ref-type="ref"}; Schmid et al., [2018](#mgg31256-bib-0037){ref-type="ref"}; Sparks, Struble, Wang, Song, & Oliphant, [2012](#mgg31256-bib-0039){ref-type="ref"}). Sequencing of SNPs may be the most accurate method to estimate FF because foreign SNPs (paternal/fetal derived) are readily apparent in the woman\'s plasma (Wataganara et al., [2016](#mgg31256-bib-0042){ref-type="ref"}). Persistently low FF remains our most important cause of no‐call and FN (Barrett et al., [2017](#mgg31256-bib-0003){ref-type="ref"}; Canick, Palomaki, Kloza, Lambert‐Messerlian, & Haddow, [2013](#mgg31256-bib-0006){ref-type="ref"}; Kim et al., [2015](#mgg31256-bib-0021){ref-type="ref"}). Low FF has been linked with high maternal weight or body mass index (Wataganara, Peter, Messerlian, Borgatta, & Bianchi, [2004](#mgg31256-bib-0045){ref-type="ref"}). Because FF is highly dynamic, re‐draw could settle only 70% of the cases with low FF from the first draw (Ashoor et al., [2013](#mgg31256-bib-0001){ref-type="ref"}).

The main limitation of our real‐life clinical performance study was the incomplete post‐test follow‐ups, particularly on low‐risk patients, thus precluding precise calculation of sensitivity, specificity, and NPV (Dar et al., [2014](#mgg31256-bib-0010){ref-type="ref"}). Some high‐risk calls may not have received confirmatory genetic testing due to the following reasons; (a) spontaneous fetal losses soon after NIPS, (b) unreported elective termination of pregnancy without karyotype confirmation, and (c) unreported birth of newborn babies with T21 due to parental concern of social stigma. Selections of subjects in most of the NIPS studies, including ours, were biased (Badeau et al., [2017](#mgg31256-bib-0002){ref-type="ref"}). The SNP‐based NIPS should not replace first trimester scan because the test is not always informative, and the PPVs for T13, XO, and SCA is relatively low. Dedicated first‐trimester anomaly scan can identify about 95% of fetuses with T18, T13, triploidy, and Turner syndrome (Wagner, Sonek, Hoopmann, Abele, & Kagan, [2016](#mgg31256-bib-0041){ref-type="ref"}). Progressive improvement of bioinformatics algorithm is likely to reduce redraw, missed call, and no‐call for those with very low FF (Larson et al., [2018](#mgg31256-bib-0022){ref-type="ref"}; McKanna et al., [2019](#mgg31256-bib-0026){ref-type="ref"}).
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